

# Mehrad Adibi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6870059/publications.pdf>

Version: 2024-02-01

17  
papers

401  
citations

933447

10  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

700  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodal kidneyâ€preserving approach in localised and locally advanced highâ€risk upper tract urothelial carcinoma. BJUI Compass, 2022, 3, 37-44.	1.3	3
2	Editorial Comment. Journal of Urology, 2022, , 101097JU0000000000000245402.	0.4	1
3	Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 176-182.	1.9	5
4	Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. European Urology Focus, 2021, 7, 397-403.	3.1	12
5	Editorial Comment. Journal of Urology, 2021, 205, 1046-1046.	0.4	0
6	Oncologic outcomes and subsequent treatment following organ sparing surgery for penile carcinoma: The University of Texas M.D. Anderson Cancer Center Experience. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 302.e19-302.e27.	1.6	4
7	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncology, The, 2020, 21, 776-785.	10.7	82
8	Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. Journal of Urology, 2018, 199, 393-400.	0.4	70
9	The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. Journal of Urology, 2016, 196, 678-684.	0.4	24
10	The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Therapeutic Advances in Urology, 2016, 8, 130-141.	2.0	57
11	Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 237.e19-237.e26.	1.6	13
12	Prediction of Pulmonary Metastasis in Renal Cell Carcinoma Patients with Indeterminate Pulmonary Nodules. European Urology, 2016, 69, 352-360.	1.9	14
13	Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 427.e17-427.e23.	1.6	35
14	Surgical considerations for patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 528-537.	1.6	23
15	Reporting Geographic and Temporal Trends in Renal Cell Carcinoma: Why Is This Important?. European Urology, 2015, 67, 531-532.	1.9	6
16	Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology, 2015, 194, 316-322.	0.4	49
17	Cytoreductive surgery in the era of targeted molecular therapy. Translational Andrology and Urology, 2015, 4, 301-9.	1.4	3